• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

FDA ten­ta­tive­ly hints at EUA, with a tri­al re­quire­ment, for Veru's new Covid drug ahead of ad­comm

3 years ago
FDA+
Coronavirus

ONO ex­er­cis­es Fate CAR-T op­tion in lat­est twist to part­ner­s' four-year deal

3 years ago
Pharma
Cell/Gene Tx

Astel­las sig­nals on­col­o­gy as­pi­ra­tions to health­care providers in ‘Change­mak­ers’ cam­paign

3 years ago
Pharma
Marketing

Mer­ck con­tin­ues rare breast can­cer cam­paign fo­cused on chal­lenges for Black women

3 years ago
Pharma
Marketing

For $700M+, Vi­a­tris nabs two biotechs as eye dis­ease em­pha­sis comes in­to view

3 years ago
Deals

With all hands on deck for lead sick­le cell tri­al, Beam pulls back clin­i­cal plans for sec­ond base edit­ing ther­a­py

3 years ago
R&D
Cell/Gene Tx

Sen­so­ri­on nabs rare pe­di­atric des­ig­na­tion for gene ther­a­py; Ava­lo sells off re­main­ing drug rights for $5M

3 years ago
News Briefing

Ku­ra On­col­o­gy se­cures up to $150M in Bris­tol My­ers eq­ui­ty in­vest­ment, loan from Her­cules Cap­i­tal

3 years ago
Financing

As Roche pre­pares to take a kid­ney dis­ease drug in­to PhI­II, Io­n­is flesh­es out the da­ta

3 years ago
R&D

Up­dat­ed: Verve's land­mark base edit­ing tri­al for car­dio drug runs in­to FDA hold

3 years ago
R&D
Cell/Gene Tx

GSK re­ports PhI­II flop for BC­MA drug — rais­ing ques­tions about its fu­ture and up­ping the stakes on com­bos

3 years ago
R&D

Am­gen maps a PhI­II jour­ney for its lat­est great car­dio drug hope­ful. Can it suc­ceed this time?

3 years ago
R&D

Lat­est news on pa­tient death in n-of-1 CRISPR tri­al; Good news for RSV; Vac­cine R&D rev­o­lu­tion; and more

3 years ago
Weekly

Up­dat­ed: Flag­ship sends a vet — post-Ru­bius im­plo­sion — in­to the breach at Reper­toire

3 years ago
People

In­smed, Al­ny­lam and oth­ers make Sci­ence's list of top 20 bio­phar­ma em­ploy­ers

3 years ago
Pharma
Marketing

N-of-1 CRISPR tri­al ends with a death as non­prof­it digs in­to what hap­pened

3 years ago
Cell/Gene Tx

Te­va reach­es $523M agree­ment with New York in lat­est opi­oid-re­lat­ed set­tle­ment

3 years ago
Pharma
Law

Per­former Teyana Tay­lor joins Joe Jonas in help­ing Merz 'ring the alar­m' on frown lines

3 years ago
Marketing

No­vo Nordisk plots com­mer­cial re­launch for We­govy as sup­plies are ex­pect­ed to re­turn

3 years ago
Pharma
Marketing

San­thera lays out op­tions in bid for com­mer­cial­iza­tion funds; Swiss biotech’s Covid work nar­rows

3 years ago
News Briefing

FDA de­lays de­ci­sion for Apel­lis' eye dis­ease drug af­ter biotech sub­mits up­dat­ed da­ta

3 years ago
R&D
FDA+

Three years af­ter un­der­whelm­ing da­ta, Lieping Chen's NextCure drops lead pro­gram

3 years ago
R&D

Avanir files WARN no­tice for 100+ lay­offs from Cal­i­for­nia as merg­er with par­ent Ot­su­ka looms

3 years ago
People

'Rule­book of mi­cro­bial ecol­o­gy': Pi­anists launch Con­cer­to to treat eczema, pro­tect crops and get rid of BO

3 years ago
Financing
Startups
First page Previous page 427428429430431432433 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times